Long-term persistence of RBD-positive memory B cells encoding neutralising antibodies in SARS-CoV-2 infection
Date
2021
Authors
Abayasingam, A.
Balachandran, H.
Agapiou, D.
Hammoud, M.
Rodrigo, C.
Keoshkerian, E.
Li, H.
Brasher, N.A.
Christ, D.
Rouet, R.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Cell Reports Medicine, 2021; 2(4):100228-1-100228-14
Statement of Responsibility
Arunasingam Abayasingam, Harikrishnan Balachandran, David Agapiou, Marianne Martinello, Rowena A. Bull, on Behalf of the COSIN Study Group
Conference Name
Abstract
Considerable concerns relating to the duration of protective immunity against SARS-CoV-2 exist, with evidence of antibody titres declining rapidly after infection and reports of reinfection. Here we monitor the antibody responses against SARS-CoV-2 receptor binding domain (RBD) for up to six months after infection. While antibody titres are maintained, about 13% of the cohort's neutralising responses return to background. However, encouragingly in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralising capacity from these memory B cells. Overall our study suggests that the loss of neutralising antibodies in plasma may be countered by the maintenance of neutralising capacity in the memory B cell repertoire.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
©2021 The Author(s). 1 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).